Alector, Inc. Share Price & Technical Analysis
ALEC · $2.21 (0.00%)
Healthcare / Biotechnology
$2.21
0.00%
Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treating prevalent neurodegenerative diseases; AL137, an anti-amyloid beta antibody paired in preclinical development for the potential treatment of Alzheime…
Price chart
Seasonality
May has 2 positive and 3 negative years (last 5 years shown)
-4% return in May, 6% avg return in past 3 year May month.
41% return in 2026, -22% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 19% | 26% | -8% | 9% | -4% | – | – | – | – | – | – | – | 41% |
| 25 | -11% | 0% | -25% | 0% | 8% | 8% | 7% | 53% | 30% | -48% | -13% | 23% | 33% |
| 24 | -24% | 17% | -15% | -15% | -2% | -8% | 33% | -13% | -11% | 7% | -48% | -27% | -108% |
| 23 | -5% | -3% | -26% | 6% | 12% | -19% | 15% | -21% | 18% | -20% | 4% | 48% | 9% |
| 22 | -23% | 1% | -10% | -32% | -7% | 15% | 1% | 3% | -7% | -6% | -9% | 10% | -66% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Emerging · Neutral
Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treating prevalent neurodegenerative diseases; AL137, an anti-amyloid beta antibody paired in preclinical development for the potential treatment of Alzheimer's disease; and AL050, a GCase enzyme replacement therapy in preclinical development for the potential treatment of Parkinson's disease and Lewy body dementia in patients having GBA1 gene mutations. The company also develops its preclinical and research pipeline comprising AL064, a tau siRNA for Alzheimer's disease and other tauopathies; ADP062-ABC, an alpha-synuclein siRNA for Parkinson's disease; and ADP065-ABC, an NLRP3 siRNA for neurodegenerative conditions. It has a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of progranulin-elevating monoclonal antibodies, including Latozinemab and Nivisnebart. The company was founded in 2013 and is headquartered in South San Francisco, California.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$234.82M
P/E ratio
—
52W high
$3.40
52W low
$1.09
Volume
3,28,072
Beta
0.65
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Alector, Inc. share price today?
- Alector, Inc. (ALEC) last traded around $2.21 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does ALEC have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for ALEC. Download the app for real-time alerts.
- How can I analyze Alector, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.